Vanessa M.Lucey, PhD

[Vanessa M.Lucey, PhD @vmlucey]

Sorry...I was hacked :( Think all fixed now

[Parker Institute @parkerici]

New Research: A novel immunotherapy-chemotherapy combo using CD40 antibody has potential to shrink pancreatic tumors. Published in @TheLancetOncol. Led by @parkerici @cancerresarch @penncancer @bmsnews + Apexigen https://t.co/TawyR9v7u6

[Cancer Research Institute @CancerResearch]

New in @cellcellpress, the CRI-@parkerici TESLA initiative identified key features of neoantigens for effective prediction as targets in #CancerVaccines and cell therapies. https://t.co/0F79i1MVbX

[Cancer Research Institute @CancerResearch]

New findings from the CRI-@parkerici Tumor nEoantigen SeLection Alliance (TESLA) initiative demonstrate key parameters for more effective prediction of tumor neoantigens with the potential to improve personalized cancer treatments. https://t.co/EOxcPWojj7

[Parker Institute @parkerici]

#FollowTheScience #IStandWithFauci

[Vanessa M.Lucey, PhD @vmlucey]

Happy to work with @parkerici on attacking cancer together. Always better to have great collaborators on board!!

[Parker Institute @parkerici]

Early on, we joined forces with @CancerResearch to accelerate cancer research. Learn more about our partnership in this our Q&A with CRI director Vanessa Lucey (@vmlucey) #silosshattered #cancerfearsPICI #CIM20 https://t.co/6UKdBY9UuM

[Vanessa M.Lucey, PhD @vmlucey]

One of my fave people!!

[Marcel van den Brink @DrMvandenBrink]

Nice portrait of a giant in immuno-oncology, a great colleague and a dear friend!

Internationally Regarded Cancer Immunologist Did Not Stray Far From Home - The ASCO Post https://t.co/xwImB8EyCj

[Vanessa M.Lucey, PhD @vmlucey]

Check out our update @Annie_Yu_CRI @samikupadhaya @CancerResearch

[Nature Reviews Drug Discovery @NatRevDrugDisc]

Interested in cancer cell therapy? Prepare for day 1 of #ASCO20 with reviews in this focus, including off-the-shelf CAR-T cells, NK cells and gammadelta T cells https://t.co/aPjWq7VAyF and an update on the clinical trial landscape https://t.co/TV4HasZxdB from @CancerResearch

[Cancer Research Institute @CancerResearch]

CRI Clinical Investigator Dr. Roisin E. O'Cearbhaill of @sloan_kettering will discuss a Phase I/ II study of chemo with anti-PD-L1 durvalumab in patients with recurrent, platinum-resistant ovarian cancer at @sgo_org’s 2020 Annual Meeting. #gynsm #SGOmtg

https://t.co/6h6LOaZRKT

[Carly Helfand @CarlyHFierce]

Happening soon: #ASCO20 preview webinar with @vmlucey of @CancerResearch and @JenniferLitton of @MDAndersonNews - come join us! https://t.co/ru5ta6ZP4Z

[Cancer Research Institute @CancerResearch]

Our team—@annie_yu_CRI, @samikupadhaya, and @vmlucey—reveals there are 1,483 active agents in development in the current cancer cell therapy pipeline in a new analysis in @NatRevDrugDisc. #ASCO20 https://t.co/dRpXRIaoia

[Vanessa M.Lucey, PhD @vmlucey]

Thanks @MelodySmithMD for your input here!!

[Cancer Research Institute @CancerResearch]

The #COVID19 pandemic had ‘moderate’ or ‘high’ impact on patient visits (delayed or canceled) in oncology clinical trials according to data from a new report in @NatRevDrugDisc conducted by CRI’s @samikupadhaya, @vmlucey, @Annie_Yu_CRI. https://t.co/l0bbuSDue9

[Cancer Research Institute @CancerResearch]

The #COVID19 pandemic had ‘moderate’ or ‘high’ impact on patient visits (delayed or canceled) in oncology clinical trials according to data from a new report in @NatRevDrugDisc conducted by CRI’s @samikupadhaya, @vmlucey, @Annie_Yu_CRI. https://t.co/l0bbuSDue9

[Katie Campbell @CampKatiee]

I'm used to using #pVACtools and predicting antigen binding for understanding how cancer is seen by the immune system. But we can also apply these tools to viruses and #COVID19. Special thanks to the investigators @parkerici @CancerResearch @UCLAJCCC https://t.co/FJ15yEqHkk

[Paul D. Rennert @PDRennert]

well. after all this is done there will still be cancer patients desperately needing novel and effective care.

back to work ...

[AACR @AACR]

After careful consideration of all available information, the AACR has made the difficult decision to postpone #AACR20, originally scheduled for April 24-29 in San Diego. Dates and location of the rescheduled meeting will be announced as soon as possible.
https://t.co/bsH7BPRzot

[Parker Institute @parkerici]

PICI is tackling the notoriously aggressive metastatic triple negative breast cancer (#mTNBC) in partnership with @BCRFcure and @CancerResearch. We’re identifying biomarkers to see who might benefit from #immunotherapy. https://t.co/o7TFhzMGpq

[Vanessa M.Lucey, PhD @vmlucey]

another conference down..SGO (Toronto) canceled. : (

[Vanessa M.Lucey, PhD @vmlucey]

Thanks @bradloncar for today and #IO360nyc for putting on another great conference!

[Brad Loncar @bradloncar]

At #IO360NYC with @vmlucey. Learnings:

🔸@CancerResearch Anna-Maria Kellen Clinical Accelerator partners w/ others to fund early stage research.
🔸CD40 for pancreatic cancer
🔸IL-8 pathway in prostate cancer

Great organization to support: https://t.co/LjsaFbQFR4